About Complex I intermediate-associated protein 30, mitochondrial
Complex I intermediate-associated protein 30, mitochondrial (NDUFAF1) is a protein
from Homo sapiens identified by UniProt accession
Q9Y375, 327 residues long.
MolForge cross-references it against 0 known binders and
253 disease associations.
Target properties
| Protein name | Complex I intermediate-associated protein 30, mitochondrial |
|---|
| UniProt accession | Q9Y375 |
|---|
| Gene | NDUFAF1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 327 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (253)
Diseases linked to this target (Open Targets).
- mitochondrial complex I deficiency · score 0.71
- type 2 diabetes mellitus · score 0.61
- diabetes mellitus · score 0.60
- polycystic ovary syndrome · score 0.60
- type 1 diabetes mellitus · score 0.58
- gestational diabetes · score 0.58
- obesity · score 0.57
- prediabetes syndrome · score 0.56
- schizophrenia · score 0.55
- insulin resistance · score 0.55
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9Y375-F1 | alphafold | PREDICTED | 72.77 | — |
Amino-acid sequence (327 residues)
MALVHKLLRG TYFLRKFSKP TSALYPFLGI RFAEYSSSLQ KPVASPGKAS SQRKTEGDLQ GDHQKEVALD ITSSEEKPDV SFDKAIRDEA IYHFRLLKDE IVDHWRGPEG HPLHEVLLEQ AKVVWQFRGK EDLDKWTVTS DKTIGGRSEV FLKMGKNNQS ALLYGTLSSE APQDGESTRS GYCAMISRIP RGAFERKMSY DWSQFNTLYL RVRGDGRPWM VNIKEDTDFF QRTNQMYSYF MFTRGGPYWQ EVKIPFSKFF FSNRGRIRDV QHELPLDKIS SIGFTLADKV DGPFFLEIDF IGVFTDPAHT EEFAYENSPE LNPRLFK
Explore Complex I intermediate-associated protein 30, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets